INTESTINAL MICRO-ORGANISMS IN THE PATHOGENESIS OF NASH AND THE ROLE OF MODULATION OF ENTERIC BACTERIA IN TREATMENT. - Enteric bacteria and non alcoholic steatohepatitis

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-001774-24-GB

Enrollment

Registered

2006-09-18

Start date

2006-09-13

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH)

Interventions

Product Name: Doxycycline Product Code: Doxycycline Pharmaceutical Form: Capsule, hard

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The presence of fatty liver or steatohepatitis on liver biopsy Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Only stable out-patients on regular follow up will be considered. All others will be excluded.

Design outcomes

Primary

Measure	Time frame
Main Objective: To demonstrate whether a six week course of doxycycline will eliminate endotoxin from the blood of patients with NAFLD/NASH and reverse the insulin resistance seen in this condition.;Secondary Objective: ;Primary end point(s): 1. Eradication of systemic endotoxaemia. 2. Alterations in insulin resistance	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026